Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 27, 2023

BUY
$1.97 - $2.91 $30,178 - $44,578
15,319 New
15,319 $30,000
Q2 2023

Jul 18, 2023

SELL
$2.57 - $3.3 $10,966 - $14,081
-4,267 Reduced 21.61%
15,478 $42,000
Q1 2023

Apr 13, 2023

SELL
$2.74 - $4.44 $542 - $879
-198 Reduced 0.99%
19,745 $59,000
Q4 2022

Jan 23, 2023

SELL
$3.89 - $8.57 $334 - $737
-86 Reduced 0.43%
19,943 $0
Q3 2022

Oct 26, 2022

SELL
$5.82 - $10.68 $91,641 - $168,167
-15,746 Reduced 44.01%
20,029 $156,000
Q2 2022

Jul 25, 2022

BUY
$4.58 - $8.72 $13,579 - $25,854
2,965 Added 9.04%
35,775 $199,000
Q1 2022

May 02, 2022

BUY
$8.6 - $15.48 $36,257 - $65,263
4,216 Added 14.74%
32,810 $282,000
Q4 2021

Jan 28, 2022

BUY
$12.51 - $22.75 $357,710 - $650,513
28,594 New
28,594 $445,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $310M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.